Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tabrecta shows promise in Real-World lung cancer study

NCT ID NCT04575025

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tracked 109 patients with a specific genetic mutation (MET exon 14 skipping) causing advanced lung cancer who were prescribed Tabrecta tablets. Researchers monitored side effects and how well the drug controlled the cancer over up to one year. The goal was to see how Tabrecta works in everyday medical practice, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tabrecta (capmatinib) tablets
What this could lead to
If results confirm benefit, this could support Tabrecta as a standard treatment for MET exon 14 skipping mutation-positive advanced lung cancer.
What could go wrong
This is an observational study without a control group, so results are less definitive. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

109 people

The number who actually took part.

Started

Nov 2020

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period. By allowing patients who started Tabrecta administration before the conclusion of a contract for this study to be included in the study population after the contract, all patients treated with Tabrecta were enrolled in this study.

Ages

0 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Novartis Investigative Site

    Kōnan, Aichi-ken, 4838704, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 457-0818, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 462-0057, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 464 8681, Japan

  • Novartis Investigative Site

    Okazaki, Aichi-ken, 444-8553, Japan

  • Novartis Investigative Site

    Toyoake, Aichi-ken, 470 1192, Japan

  • Novartis Investigative Site

    Toyota, Aichi-ken, 470-0343, Japan

  • Novartis Investigative Site

    Daisen, Akita, 014-0027, Japan

  • Novartis Investigative Site

    Hachinohe, Aomori, 031-0011, Japan

  • Novartis Investigative Site

    Sakura, Chiba, 285-8741, Japan

  • Novartis Investigative Site

    Fukui-shi, Fukui, 918-8501, Japan

  • Novartis Investigative Site

    Yoshida-gun, Fukui, 910-1193, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 811-1395, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 814 0180, Japan

  • Novartis Investigative Site

    Iizuka, Fukuoka, 820-0076, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 802-0077, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 8058508, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 806-8501, Japan

  • Novartis Investigative Site

    Fukushima, Fukushima, 960 1295, Japan

  • Novartis Investigative Site

    Ōgaki, Gifu, 503-8502, Japan

  • Novartis Investigative Site

    Higashihiroshima, Hiroshima, 739-0041, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 003-0804, Japan

  • Novartis Investigative Site

    Akashi, Hyōgo, 673-8558, Japan

  • Novartis Investigative Site

    Himeji, Hyōgo, 670-8520, Japan

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 663 8501, Japan

  • Novartis Investigative Site

    Tsuchiura, Ibaraki, 300-0028, Japan

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 305-8558, Japan

  • Novartis Investigative Site

    Kan’onjichō, Kagawa-ken, 769-1695, Japan

  • Novartis Investigative Site

    Sakaidechō, Kagawa-ken, 762-8550, Japan

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, 760-0017, Japan

  • Novartis Investigative Site

    Fujisawa, Kanagawa, 251-8550, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 216-8511, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 252-0375, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 220-8521, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 221-0855, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 232 0024, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 234-0054, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 236 0037, Japan

  • Novartis Investigative Site

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    Yokkaichi, Mie-ken, 510-8567, Japan

  • Novartis Investigative Site

    Miyakonojō, Miyazaki, 885-0014, Japan

  • Novartis Investigative Site

    Matsumoto, Nagano, 390-8621, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 701-0192, Japan

  • Novartis Investigative Site

    Okayama, Okayama-ken, 700-8558, Japan

  • Novartis Investigative Site

    Kishiwada, Osaka, 596-8501, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 534-0021, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 540-0006, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 541-8567, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 543-8555, Japan

  • Novartis Investigative Site

    Saga, Saga-ken, 849-8501, Japan

  • Novartis Investigative Site

    Kawaguchi, Saitama, 332-8558, Japan

  • Novartis Investigative Site

    Kumagaya, Saitama, 360-0197, Japan

  • Novartis Investigative Site

    Saitama, Saitama, 330 8503, Japan

  • Novartis Investigative Site

    Saitama, Saitama, 330-8553, Japan

  • Novartis Investigative Site

    Izumo, Shimane, 693 8501, Japan

  • Novartis Investigative Site

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, 113-8431, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Edogawa City, Tokyo, 133-0052, Japan

  • Novartis Investigative Site

    Kiyose, Tokyo, 204-8585, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, 135 8550, Japan

  • Novartis Investigative Site

    Minato, Tokyo, 108-0073, Japan

  • Novartis Investigative Site

    Minato Ku, Tokyo, 105-8470, Japan

  • Novartis Investigative Site

    Minato-ku, Tokyo, 105-8471, Japan

  • Novartis Investigative Site

    Shibuya City, Tokyo, 150-8935, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    Tama, Tokyo, 206-8512, Japan

  • Novartis Investigative Site

    Toyama, Toyama, 930-0194, Japan

  • Novartis Investigative Site

    Higashi Okitama, Yamagata, 9920601, Japan

  • Novartis Investigative Site

    Ube, Yamaguchi, 755-0241, Japan

  • Novartis Investigative Site

    Aomori, 030 8553, Japan

  • Novartis Investigative Site

    Chiba, 261-0001, Japan

  • Novartis Investigative Site

    Hiroshima, 734 8530, Japan

  • Novartis Investigative Site

    Kumamoto, 860-8556, Japan

  • Novartis Investigative Site

    Kumamoto, 861-4193, Japan

  • Novartis Investigative Site

    Osaka, 530 0005, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.